Thyroid Antibodies Decoded: Which to Order, When They Matter, and When They Don't
Three antibodies, three different clinical stories—and the autoimmune crossover that ties them to everything else you're managing.
Thyroid antibody testing is one of the most commonly ordered—and most commonly misinterpreted—panels in primary care. Every week I see providers ordering the full antibody panel on every patient with an abnormal TSH, or panicking about a positive anti-TPO in someone with a perfectly normal thyroid. Let's sort out what each antibody actually tells you and when it changes your management.
The Three Thyroid Antibodies
Anti-TPO (Thyroid Peroxidase Antibody)
The workhorse antibody for Hashimoto's thyroiditis. TPO is the enzyme that catalyzes thyroid hormone synthesis. Anti-TPO antibodies activate complement and are directly involved in thyroid tissue destruction. Present in ~95% of Hashimoto's patients and ~70% of Graves' patients. This is the most sensitive thyroid antibody for detecting autoimmune thyroid disease (AITD).
The catch: anti-TPO is also positive in about 10% of the general population who have no thyroid disease—and this prevalence rises with age and female sex. A positive anti-TPO alone, without thyroid dysfunction, doesn't require treatment.
Anti-Tg (Thyroglobulin Antibody)
Present in 30–50% of Hashimoto's patients and at about half that rate in Graves' disease. Less sensitive than anti-TPO for diagnosing AITD. Per Mayo Clinic Laboratories guidance, anti-Tg should only be ordered if anti-TPO is negative but clinical suspicion for AITD remains high.
Critical second role: Anti-Tg is essential in the monitoring of differentiated thyroid cancer after treatment. Thyroglobulin (Tg) is used as a tumor marker post-thyroidectomy, but anti-Tg antibodies interfere with the Tg assay—causing falsely low results on immunometric assays. If anti-Tg is present, the Tg tumor marker is unreliable, and rising anti-Tg titers themselves may indicate recurrence.
TRAb / TSI (TSH Receptor Antibodies / Thyroid-Stimulating Immunoglobulin)
The Graves' disease antibody. TSI binds to the TSH receptor and mimics TSH, causing unregulated thyroid hormone production. TSI is ~96% sensitive and ~99% specific for Graves' disease. There are actually three types of TSH receptor antibodies—stimulating (TSI), blocking, and neutral—but TSI is the clinically actionable one.
Nomenclature warning: TRAb, TBII, TSI, and LATS all refer to related but distinct assays. TRAb/TBII measures all receptor antibodies (stimulating + blocking + neutral). TSI measures only the stimulating type. In most clinical contexts, TSI is what you want when confirming Graves' disease.
The Master Decision Table: Which Antibody, When
| Clinical Scenario | What to Order | Why |
|---|---|---|
| Elevated TSH, suspect Hashimoto's | Anti-TPO | Most sensitive marker; confirms autoimmune etiology. Anti-Tg adds little if TPO is positive. |
| Elevated TSH, anti-TPO negative, still suspect AITD | Anti-Tg | ~5% of Hashimoto's patients are TPO-negative but Tg-positive |
| Subclinical hypothyroidism (mildly elevated TSH, normal T4) | Anti-TPO | Positive anti-TPO predicts progression to overt hypothyroidism; may influence treatment decision |
| Suppressed TSH, suspect Graves' disease | TSI (or TRAb) | Confirms Graves' vs. other causes of hyperthyroidism (toxic nodule, thyroiditis, exogenous T4) |
| Hyperthyroidism when radioactive iodine uptake is contraindicated or unavailable | TSI | Can confirm Graves' without imaging |
| Pregnant with Graves' disease (or history of Graves') | TRAb/TSI | Maternal TRAb crosses the placenta; high titers predict neonatal thyrotoxicosis risk |
| Post-thyroidectomy thyroid cancer monitoring | Anti-Tg (with every thyroglobulin measurement) | Anti-Tg interferes with Tg tumor marker assays; rising anti-Tg may signal recurrence |
| Positive ANA workup, looking for cause | Anti-TPO + Anti-Tg | Thyroid antibodies may be the sole explanation for ANA positivity (speckled or homogeneous pattern) |
| Euthyroid patient, no symptoms | Nothing | Don't screen asymptomatic patients for thyroid antibodies |
The Pitfalls: What Trips Up Clinicians
1. Positive Anti-TPO in a Euthyroid Patient ≠ Disease
About 10% of the general population—and up to 25% of women over 60—will have positive anti-TPO with completely normal thyroid function. This does not require treatment. It does mean the patient has a higher risk of developing overt hypothyroidism over time (about 2–4% per year if TSH is already in the high-normal range). The appropriate response is periodic TSH monitoring, not levothyroxine.
The combination of positive anti-TPO + mildly elevated TSH is where the treatment decision gets nuanced. Many endocrinologists will recommend starting levothyroxine in this scenario, especially if the patient is symptomatic, has a goiter, is trying to conceive, or has TSH >10. Antibody-negative subclinical hypothyroidism is less likely to progress and may be observed.
2. Don't Routinely Order Anti-Tg for Hashimoto's Diagnosis
Anti-TPO is more sensitive and has equal specificity. Ordering both together for initial diagnosis adds cost without meaningful diagnostic yield. Save anti-Tg for when TPO is negative but suspicion is high, or for thyroid cancer monitoring.
3. Thyroid Antibodies Can Explain a Positive ANA
This was highlighted in the Bellocchi autoimmune serologic testing review that started this whole blog series. Anti-TPO and anti-Tg antibodies can cause ANA positivity, typically with a speckled or homogeneous pattern. In a patient with positive ANA but no clinical features of CTD, always check thyroid antibodies. Hashimoto's may be the sole explanation—and it's far more common than lupus.
If you're working up a positive ANA and the patient has no joint pain, no rash, no Raynaud's, and no oral ulcers—but they do have fatigue and a TSH of 6.2—check anti-TPO before chasing an ENA panel. You may save the patient a rheumatology referral.
4. TSI vs. TRAb: Know What You're Ordering
The nomenclature is genuinely confusing. TRAb (or TBII) assays measure all TSH receptor antibodies—stimulating, blocking, and neutral. TSI assays specifically measure only stimulating antibodies. For confirming Graves' disease, TSI is more specific. Some labs report "TRAb" when they mean TBII; others use TRAb to mean TSI. Know what your lab is actually running, and when in doubt, specifically order TSI.
5. Graves' Disease Patients Can Be TRAb/TSI-Negative (Rarely)
About 5% of Graves' patients are seronegative for TSI. If the clinical picture is classic (suppressed TSH, elevated free T4, diffuse goiter, ophthalmopathy) but TSI is negative, a radioactive iodine uptake scan will confirm the diagnosis. Don't exclude Graves' based solely on a negative antibody.
6. Biotin Interference
This is a practical pitfall that catches people. Biotin (vitamin B7)—found in many hair, skin, and nail supplements—can interfere with immunoassays used for thyroid testing, including antibody tests. It can cause falsely low TSH and falsely high free T4 (mimicking hyperthyroidism), and can interfere with antibody measurements. Patients should stop biotin supplements for at least 12 hours (some labs recommend 48–72 hours) before thyroid testing.
7. Pregnancy: When Antibodies Really Matter
Thyroid antibodies take on special significance in pregnancy:
- Positive anti-TPO in euthyroid pregnant women increases risk of miscarriage and preterm birth. Some guidelines recommend levothyroxine in this population, though this remains debated.
- TRAb/TSI in pregnant women with Graves' disease (active or history of Graves'): these antibodies cross the placenta and can cause neonatal thyrotoxicosis. Check TRAb/TSI in early pregnancy and again at 18–22 weeks; high titers warrant neonatal monitoring.
- Postpartum thyroiditis: anti-TPO positive women have a significantly higher risk of developing postpartum thyroiditis. Persistently elevated antibodies after postpartum thyroiditis predict permanent hypothyroidism.
8. Immune Checkpoint Inhibitor Thyroiditis
For NPs managing oncology patients: immune checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab) frequently cause thyroid adverse effects. Patients with pre-existing thyroid antibodies are at higher risk. Checking anti-TPO before starting immunotherapy can help predict who will develop thyroiditis, and thyroid function should be monitored throughout treatment.
The Autoimmune Cluster
Autoimmune thyroid disease rarely travels alone. If you diagnose Hashimoto's or Graves', keep these associated conditions on your radar:
- Type 1 diabetes — screen if symptomatic
- Celiac disease — consider if GI symptoms, anemia, or weight changes
- Pernicious anemia — check B12 and anti-intrinsic factor if macrocytic anemia
- Vitiligo, alopecia areata — skin manifestations of shared autoimmune susceptibility
- Addison's disease — rare but part of autoimmune polyglandular syndrome
- SLE, Sjögren's, RA — broader CTD spectrum
- Primary Raynaud's — may be associated with autoimmune thyroiditis
Quick-Reference: The Ordering Algorithm
| TSH Result | Clinical Question | Order |
|---|---|---|
| Elevated (hypo) | Is this autoimmune? | Anti-TPO. If negative, consider anti-Tg. |
| Mildly elevated (subclinical) | Will this progress? | Anti-TPO (positive = higher risk of progression) |
| Suppressed (hyper) | Is this Graves'? | TSI (or TRAb). Do NOT use anti-TPO to diagnose Graves'. |
| Normal | ANA positive, no CTD features | Anti-TPO + anti-Tg (thyroid antibodies may explain ANA) |
| Normal | No symptoms, no clinical indication | Don't order thyroid antibodies |
| Any | Pregnant with Graves' (active or history) | TRAb/TSI (1st trimester and 18–22 weeks) |
| Any | Thyroid cancer monitoring post-treatment | Anti-Tg (with every thyroglobulin tumor marker) |
Bottom Line
Thyroid antibody testing is powerful when used correctly. Anti-TPO is your go-to for Hashimoto's and subclinical hypothyroidism risk stratification. TSI is what confirms Graves'. Anti-Tg is a niche player—reserve it for TPO-negative suspected AITD and thyroid cancer monitoring. And remember: a positive antibody in a euthyroid patient is not a diagnosis. It's a risk factor that requires monitoring, not reflexive treatment.
Most importantly for this series: thyroid antibodies are the hidden explanation behind many "unexplained" positive ANAs. If you take nothing else from this post, remember to check anti-TPO and anti-Tg when you're chasing a positive ANA in a patient who just doesn't look like lupus.
Stay sharp out there.
Comments
Post a Comment